The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Immune Thrombocytopenia Treatment Market Research Report 2025
Synopsis
Immune thrombocytopenia (ITP) is a bleeding disorder caused by thrombocytopenia not associated with a systemic disease. Typically, it is chronic in adults, but it is usually acute and self-limited in children. Spleen size is normal in the absence of another underlying condition.
The global Immune Thrombocytopenia Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Immune Thrombocytopenia Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Immune Thrombocytopenia Treatment.
Report Scope
The Immune Thrombocytopenia Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Immune Thrombocytopenia Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Immune Thrombocytopenia Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
CSL Behring
Amgen
F.Hoffmann-La Roche
Kyowa Hakko Kirin
Rigel Pharmaceuticals
Shionogi
Dova Pharmaceuticals
Novartis
Shire
Ligand Pharmaceuticals
GSK
Grifols Biologicals
Jiangsu Hengrui Pharmaceutical
Segment by Type
Corticosteroids
Intravenous Immunoglobulin (IVIG)
Anti-D Immunoglobulin
Thrombopoietin Receptor Agonist (TPO-RA)
Others
Segment by Application
Hospitals and Clinics
Research and Academic Institutes
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Immune Thrombocytopenia Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Immune thrombocytopenia (ITP) is a bleeding disorder caused by thrombocytopenia not associated with a systemic disease. Typically, it is chronic in adults, but it is usually acute and self-limited in children. Spleen size is normal in the absence of another underlying condition.
The global Immune Thrombocytopenia Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Immune Thrombocytopenia Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Immune Thrombocytopenia Treatment.
Report Scope
The Immune Thrombocytopenia Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Immune Thrombocytopenia Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Immune Thrombocytopenia Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
CSL Behring
Amgen
F.Hoffmann-La Roche
Kyowa Hakko Kirin
Rigel Pharmaceuticals
Shionogi
Dova Pharmaceuticals
Novartis
Shire
Ligand Pharmaceuticals
GSK
Grifols Biologicals
Jiangsu Hengrui Pharmaceutical
Segment by Type
Corticosteroids
Intravenous Immunoglobulin (IVIG)
Anti-D Immunoglobulin
Thrombopoietin Receptor Agonist (TPO-RA)
Others
Segment by Application
Hospitals and Clinics
Research and Academic Institutes
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Immune Thrombocytopenia Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Immune Thrombocytopenia Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Corticosteroids
1.2.3 Intravenous Immunoglobulin (IVIG)
1.2.4 Anti-D Immunoglobulin
1.2.5 Thrombopoietin Receptor Agonist (TPO-RA)
1.2.6 Others
1.3 Market by Application
1.3.1 Global Immune Thrombocytopenia Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals and Clinics
1.3.3 Research and Academic Institutes
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Immune Thrombocytopenia Treatment Market Perspective (2019-2030)
2.2 Immune Thrombocytopenia Treatment Growth Trends by Region
2.2.1 Global Immune Thrombocytopenia Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Immune Thrombocytopenia Treatment Historic Market Size by Region (2019-2024)
2.2.3 Immune Thrombocytopenia Treatment Forecasted Market Size by Region (2025-2030)
2.3 Immune Thrombocytopenia Treatment Market Dynamics
2.3.1 Immune Thrombocytopenia Treatment Industry Trends
2.3.2 Immune Thrombocytopenia Treatment Market Drivers
2.3.3 Immune Thrombocytopenia Treatment Market Challenges
2.3.4 Immune Thrombocytopenia Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Immune Thrombocytopenia Treatment Players by Revenue
3.1.1 Global Top Immune Thrombocytopenia Treatment Players by Revenue (2019-2024)
3.1.2 Global Immune Thrombocytopenia Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Immune Thrombocytopenia Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Immune Thrombocytopenia Treatment Revenue
3.4 Global Immune Thrombocytopenia Treatment Market Concentration Ratio
3.4.1 Global Immune Thrombocytopenia Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Immune Thrombocytopenia Treatment Revenue in 2023
3.5 Immune Thrombocytopenia Treatment Key Players Head office and Area Served
3.6 Key Players Immune Thrombocytopenia Treatment Product Solution and Service
3.7 Date of Enter into Immune Thrombocytopenia Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Immune Thrombocytopenia Treatment Breakdown Data by Type
4.1 Global Immune Thrombocytopenia Treatment Historic Market Size by Type (2019-2024)
4.2 Global Immune Thrombocytopenia Treatment Forecasted Market Size by Type (2025-2030)
5 Immune Thrombocytopenia Treatment Breakdown Data by Application
5.1 Global Immune Thrombocytopenia Treatment Historic Market Size by Application (2019-2024)
5.2 Global Immune Thrombocytopenia Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Immune Thrombocytopenia Treatment Market Size (2019-2030)
6.2 North America Immune Thrombocytopenia Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Immune Thrombocytopenia Treatment Market Size by Country (2019-2024)
6.4 North America Immune Thrombocytopenia Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Immune Thrombocytopenia Treatment Market Size (2019-2030)
7.2 Europe Immune Thrombocytopenia Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Immune Thrombocytopenia Treatment Market Size by Country (2019-2024)
7.4 Europe Immune Thrombocytopenia Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Immune Thrombocytopenia Treatment Market Size (2019-2030)
8.2 Asia-Pacific Immune Thrombocytopenia Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Immune Thrombocytopenia Treatment Market Size (2019-2030)
9.2 Latin America Immune Thrombocytopenia Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Immune Thrombocytopenia Treatment Market Size by Country (2019-2024)
9.4 Latin America Immune Thrombocytopenia Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Immune Thrombocytopenia Treatment Market Size (2019-2030)
10.2 Middle East & Africa Immune Thrombocytopenia Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 CSL Behring
11.1.1 CSL Behring Company Detail
11.1.2 CSL Behring Business Overview
11.1.3 CSL Behring Immune Thrombocytopenia Treatment Introduction
11.1.4 CSL Behring Revenue in Immune Thrombocytopenia Treatment Business (2019-2024)
11.1.5 CSL Behring Recent Development
11.2 Amgen
11.2.1 Amgen Company Detail
11.2.2 Amgen Business Overview
11.2.3 Amgen Immune Thrombocytopenia Treatment Introduction
11.2.4 Amgen Revenue in Immune Thrombocytopenia Treatment Business (2019-2024)
11.2.5 Amgen Recent Development
11.3 F.Hoffmann-La Roche
11.3.1 F.Hoffmann-La Roche Company Detail
11.3.2 F.Hoffmann-La Roche Business Overview
11.3.3 F.Hoffmann-La Roche Immune Thrombocytopenia Treatment Introduction
11.3.4 F.Hoffmann-La Roche Revenue in Immune Thrombocytopenia Treatment Business (2019-2024)
11.3.5 F.Hoffmann-La Roche Recent Development
11.4 Kyowa Hakko Kirin
11.4.1 Kyowa Hakko Kirin Company Detail
11.4.2 Kyowa Hakko Kirin Business Overview
11.4.3 Kyowa Hakko Kirin Immune Thrombocytopenia Treatment Introduction
11.4.4 Kyowa Hakko Kirin Revenue in Immune Thrombocytopenia Treatment Business (2019-2024)
11.4.5 Kyowa Hakko Kirin Recent Development
11.5 Rigel Pharmaceuticals
11.5.1 Rigel Pharmaceuticals Company Detail
11.5.2 Rigel Pharmaceuticals Business Overview
11.5.3 Rigel Pharmaceuticals Immune Thrombocytopenia Treatment Introduction
11.5.4 Rigel Pharmaceuticals Revenue in Immune Thrombocytopenia Treatment Business (2019-2024)
11.5.5 Rigel Pharmaceuticals Recent Development
11.6 Shionogi
11.6.1 Shionogi Company Detail
11.6.2 Shionogi Business Overview
11.6.3 Shionogi Immune Thrombocytopenia Treatment Introduction
11.6.4 Shionogi Revenue in Immune Thrombocytopenia Treatment Business (2019-2024)
11.6.5 Shionogi Recent Development
11.7 Dova Pharmaceuticals
11.7.1 Dova Pharmaceuticals Company Detail
11.7.2 Dova Pharmaceuticals Business Overview
11.7.3 Dova Pharmaceuticals Immune Thrombocytopenia Treatment Introduction
11.7.4 Dova Pharmaceuticals Revenue in Immune Thrombocytopenia Treatment Business (2019-2024)
11.7.5 Dova Pharmaceuticals Recent Development
11.8 Novartis
11.8.1 Novartis Company Detail
11.8.2 Novartis Business Overview
11.8.3 Novartis Immune Thrombocytopenia Treatment Introduction
11.8.4 Novartis Revenue in Immune Thrombocytopenia Treatment Business (2019-2024)
11.8.5 Novartis Recent Development
11.9 Shire
11.9.1 Shire Company Detail
11.9.2 Shire Business Overview
11.9.3 Shire Immune Thrombocytopenia Treatment Introduction
11.9.4 Shire Revenue in Immune Thrombocytopenia Treatment Business (2019-2024)
11.9.5 Shire Recent Development
11.10 Ligand Pharmaceuticals
11.10.1 Ligand Pharmaceuticals Company Detail
11.10.2 Ligand Pharmaceuticals Business Overview
11.10.3 Ligand Pharmaceuticals Immune Thrombocytopenia Treatment Introduction
11.10.4 Ligand Pharmaceuticals Revenue in Immune Thrombocytopenia Treatment Business (2019-2024)
11.10.5 Ligand Pharmaceuticals Recent Development
11.11 GSK
11.11.1 GSK Company Detail
11.11.2 GSK Business Overview
11.11.3 GSK Immune Thrombocytopenia Treatment Introduction
11.11.4 GSK Revenue in Immune Thrombocytopenia Treatment Business (2019-2024)
11.11.5 GSK Recent Development
11.12 Grifols Biologicals
11.12.1 Grifols Biologicals Company Detail
11.12.2 Grifols Biologicals Business Overview
11.12.3 Grifols Biologicals Immune Thrombocytopenia Treatment Introduction
11.12.4 Grifols Biologicals Revenue in Immune Thrombocytopenia Treatment Business (2019-2024)
11.12.5 Grifols Biologicals Recent Development
11.13 Jiangsu Hengrui Pharmaceutical
11.13.1 Jiangsu Hengrui Pharmaceutical Company Detail
11.13.2 Jiangsu Hengrui Pharmaceutical Business Overview
11.13.3 Jiangsu Hengrui Pharmaceutical Immune Thrombocytopenia Treatment Introduction
11.13.4 Jiangsu Hengrui Pharmaceutical Revenue in Immune Thrombocytopenia Treatment Business (2019-2024)
11.13.5 Jiangsu Hengrui Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
